Killing potential of circulating neutrophils in renal tumors

Ilseya R. Myagdieva; Мягдиева И. Р.; Tatyana V. Abakumova; Абакумова Т. В.; Dinara R. Dolgova; Долгова Д. Р.; Oleg Yu. Gorshkov; Горшков О. Ю.; Tatyana P. Gening; Генинг Т. П.; Galiya V. Galieva; Галиева Г. В.

doi:10.22363/2313-0245-2025-29-3-312-320

Киллинговый потенциал циркулирующих нейтрофилов при опухолях почки

Авторы: Мягдиева И.Р.¹, Абакумова Т.В.¹, Долгова Д.Р.¹, Горшков О.Ю.², Генинг Т.П.¹, Галиева Г.В.¹
Учреждения:
1. Ульяновский государственный университет
2. Областной клинический онкологический диспансер
Выпуск: Том 29, № 3 (2025): ОНКОЛОГИЯ
Страницы: 312-320
Раздел: ОНКОЛОГИЯ
URL: https://journals.rudn.ru/medicine/article/view/46086
DOI: https://doi.org/10.22363/2313-0245-2025-29-3-312-320
EDN: https://elibrary.ru/OZADDV
ID: 46086

Цитировать

Полный текст

Аннотация
Полный текст
Об авторах
Список литературы
Дополнительные файлы
Статистика

Аннотация

Актуальность. В настоящее время значительный интерес представляет изучение роли нейтрофилов в развитии рака почки. Исследование иммунопатогенеза рака почки определяется необходимостью использования комбинированного лечения с применением иммунотерапии. Известна способность нейтрофилов проявлять как про- так и противоопухолевые свойства, которые связаны с уровнем поверхностных рецепторов CD11b, CD16, CD63, CD66b и киллинговой активностью нейтрофилов. Цель — оценить киллинговый потенциал циркулирующих нейтрофилов при опухолях почки. Материалы и методы. Объектом исследования явились циркулирующие нейтрофилы пациентов c верифицированным раком почки (n = 74), пациентов с доброкачественными новообразованиями почки (n = 18) и условно здоровых доноров (n = 22). Исследование фенотипа выделенных нейтрофилов проводили методом проточной цитометрии. Подсчет внеклеточных нейтрофильных ловушек проводили по методу Долгушина И.И. Результаты и обсуждение. Анализ процента внеклеточных нейтрофильных ловушек показал увеличение их количества в группах пациентов с раком почки, как I–II, так и III–IV стадий относительно группы контроля и группы пациентов с доброкачественными новообразованиями почки. Было обнаружено повышение индекса нейтрофильных ловушек в группах пациентов с раком почки I–II и III–IV стадий относительно контрольной группы и группы пациентов с доброкачественными новообразованиями почки. При оценке фагоцитарной активности и индекса фагоцитарной активности было обнаружено значимое увеличение данных показателей в группах пациентов с раком почки относительно контрольной группы и группы пациентов с доброкачественными новообразованиями почки. Обнаружена корреляционная связь между процентом внеклеточных нейтрофильных ловушек (r = 0,438, p = 0,001), фагоцитарной активностью (r = 0,431, р = 0,001) и индексом фагоцитарной активности (r = 0,507, р = 0,001) нейтрофилов со стадией рака почки. Установлено значимое повышение процента нейтрофилов, экспрессирующих рецепторы CD66b как на начальных, так и на распространенных стадиях рака почки относительно группы с доброкачественными новообразованиями почки и группы контроля. В мультивариантной регрессии Кокса выявлено возрастание риска возникновения рака почки при повышении экспрессии CD66b, индекса внеклеточных нейтрофильных ловушек, фагоцитарной активности и индекса фагоцитарной активности циркулирующих нейтрофилов (R2 = 0,728, χ² = 58,1, р = 0,001). Для дифференциальной диагностики между доброкачественными новообразованиями почки и раком почки статистическую значимость демонстрировали совместно процент CD66b+ нейтрофилов, индекс внеклеточных нейтрофильных ловушек, фагоцитарной активности нейтрофилов и индекса фагоцитарной активности. Площадь под кривой (AUC) модели составила 0,983, и рак почки мог быть диагностирован с вероятностью 94,3% (Spec. = 0,889, Sens. = 0,962). Выводы. Таким образом, увеличение CD66b+ нейтрофилов и активация высвобождения внеклеточных ловушек свидетельствует о повышении киллинговой активности нейтрофилов при раке почки. Одновременное определение количества CD66b+ нейтрофилов, индекса внеклеточных нейтрофильных ловушек, фагоцитарной активности и индекса фагоцитарной активности может использоваться для дифференциальной диагностики между доброкачественными новообразованиями почки и рака почки.

Ключевые слова

нейтрофилы, рак почки, CD11b, CD16, CD66b, CD63, внеклеточные нейтрофильные ловушки

Полный текст

Introduction

Clear cell renal cell carcinoma (RC) is the most common type of renal cancer (about 70% of cases). The leading role in its treatment belongs to the surgical method. However, already at the time of diagnosis, a significant proportion of patients are diagnosed with disseminated RC, which determines the need for combined treatment with immunotherapy [1]. Currently, the number of studies aimed at studying the role of neutrophils (Nph) in RC is growing [2, 3]. The ability of Nph to exhibit both pro- and antitumor properties has been shown [4].

The level of expression of surface receptors determines the functional activity of Nph. Thus, CD11b, CD16, CD63 and CD66b allow identifying mature and activated Nph [5]. Thus, CD11b mediates chemotaxis of Nph to the site of inflammation, adhesion, phagocytosis, respiratory burst and degranulation [6]. CD16 (FcγRIII) is a marker of Nph capable of cytotoxic action, degranulation, oxygen burst and proliferation [6]. CD66b receptors are expressed by mature, activated and degranulating Nph [7]. CD11b+CD16+ is a subpopulation of mature Nph capable of phagocytosis and degranulation [8]. The receptors of maturity, activation, degranulation and cytotoxicity CD16, CD63, CD66b determine the phenotype of neutrophils, which have a high capacity to form extracellular neutrophil traps (NETs) [9].

It is known that NETs play an important role in the occurrence and development of pathological processes [10, 11]. While the positive effects of NETs in the fight against pathogens have already been largely described, their negative role has also become known, including in carcinogenesis. NETs can have potential antitumor effects due to the direct destruction of cancer cells or activation of the immune system, releasing a number of cytotoxic substances that destroy tumor cells, block tumor growth and the formation of metastases [12, 13]. However, many studies indicate that NETs, ensuring the spread of tumor cells to organs and tissues, are capable of exerting a protumorogenic effect and play an important role in the progression and metastasis of tumors, including in RC [14]. The phenotype of Nph is associated with the tumor process and stage, and can determine the growth and progression of RC [9]. However, this question has not been fully studied.

The aim of this work was to evaluate the killing potential of circulating Nph in renal tumors.

Materials and methods

The object of the study were circulating Nph of patients with verified RC (Table 1), conditionally healthy donors (control group) and patients with renal benign neoplasms (RBN) (oncocytoma, angiolipoma, renal cyst) (Table 1). Nph were isolated from leukocyte suspension on a double density gradient of Ficoll-Verografin solutions. The isolated Nph were brought to a concentration of 5Н10⁶ cells/ml. The purity of the Nph fraction was 92–94%. The viability of Nph in the test with 0.5% trypan blue was 95%. The phenotype of the isolated Nph was studied by flow cytometry (BioSino, China) using monoclonal antibodies (Sony Biotechnology, USA) labeled with FITC (fluoresceinisothiocyanate), PE (phycoerythrin), PC5 (phycoerythrin-cyanin 5): CD11b, CD16, CD63, CD66b, CD95. NETs were counted according to the method of Dolgushin I.I. et al. (2010). The number traps (NT,%) of neutrophil was determined — the number of neutrophil traps containing yeast activator cells from 100 counted network-like structures and the neutrophil trap index (TI, c. u.) — the number of yeast activators in 100 counted traps per 1 structure, phagocytic activity (PA,%) and phagocytic index (PI, c. u.).

Statistical analysis

The sets of quantitative indicators, the distribution of which differed from the normal one, were described using the median (Me) values and the lower and upper quartiles (Q₁ – Q₃). The statistical significance of the differences was assessed using the Mann-Whitney U-test. To study the relationship between quantitative variables, the Spearman correlation coefficient was calculated. To assess the association of the studied indicators and the degree of differentiation, sensitivity and specificity were calculated, as well as ROC analysis. Statistical processing was performed using Statistica v. 13 and Jamovi 2.3.28 software. Differences were considered statistically significant at p ˂ 0.05.

Table 1
Clinical characteristics of patients included in the study

Group	Clinical characteristics	Meaning
Renal cancer, n = 74	Age — median (Q₁– Q₃), years	66 (58–70)
	Absolute leukocyte count x10⁹/l	7.02 (5.80–8.31)
	Absolute neutrophil count x10⁹/l	3.46 (2.70–4.90)
	NLR (Q₁– Q₃)	1.33 (1.01–2.19)
	Sex
	male	36
	female	38
	Histotype:
	Clear cell carcinoma	74
	Stage of the disease:
	I–II	40
	III–IV	34
Renal benign neoplasms n = 18	Age — median (Q₁– Q₃), years	68 (56–75)
	Absolute leukocyte count x10⁹/l	4.60 (4.30–5.65)
	Absolute neutrophil count x10⁹/l	2.58 (2.10–2.68)
	NLR (Q₁– Q₃)	1.19 (1.18–1.68)
	Sex
	male	0
	female	18
Control groupn = 22	Age — median (Q₁– Q₃), years	54(52–66)
	Absolute leukocyte count x10⁹/l	6.10 (5.28–6.88)
	Absolute neutrophil count x10⁹/l	3.30 (2.82–3.97)
	NLR (Q₁– Q₃)	1.73 (1.23–1.88)
	Sex
	male	8
	female	14

Note: NLR — neutrophil-lymphocyte ratio.

Results and discussion

During the study, we did not find any significant change in the absolute amount of Nph in the blood of patients in the study groups. According to studies [15, 16], NETs are associated with tumor cell proliferation and affect tumor development. Analysis of the percentage of NETs showed an increase in their number in groups of patients with RC, both I–II and III–IV stages of RC, relative to the control group and the group of patients with RBN (Table 2).

Table 2
Indicators of neutrophil extracellular traps and phagocytic activity of circulating neutrophils in the study groups, Me (Q₁– Q₃)

Indicators	Control group (n = 22)	Renal benign neoplasms (n = 18)	Renal cancer stage I–II (n = 50)	Renal cancer stage III–IV(n = 34)
Number traps, %	4.00 (3.00–4.75)	3.00 (3.00–4.00)	5 (4.00–7.00)^*	6.00 (5.00–8.00)^*
p	-	-	p1 = 0.001, p2 = 0.001	p1 = 0.001, p2 = 0.001
Index trap, у. е.	1.33(1.00–1.90)	1.55 (1.45–1.60)	1.69 (1.48–1.85)^*	1.63 (1.50–2.00)^*
p	-	-	p1 = 0.007, p2 = 0.022	p1 = 0.012, p2 = 0.024
Phagocyticactivity, %	13.00 (10.30–12.30)	7.00 (5.00–11.00)^*	10.00 (8.75–12.30)^*	14.00 (10.00–17.00)^*
p	-	p1 = 0.001	p2 = 0.006	p1 = 0.189, p2 = 0.001, p3 = 0.001
Phagocytic activity index, у. е.	0.24 (0.19–0.29)	0.17 (0.07–0.39)	0.26 (0.20–0.39)^*	0.32 (0.29–0.36)^*
p	-	-	p2 = 0.026	p1 = 0.004, p2 = 0.024, p3 = 0.001

Note: p1 — reliability of differences in indicators from the values of the control group; p2 — reliability of differences in indicators from the values in the group with benign neoplasms; p3 — reliability of differences in indicators from the values of the previous stage of renal cancer; reliability of differences according to the Mann-Whitney criterion: * (p < 0.05).

We also found an increase in IT in the groups of patients with stages I–II and III–IV RC relative to the control group and the group of patients with RBN. When assessing PA and PI, a significant increase in these parameters was found in the groups of patients with RC relative to the control group and the group of patients with RBN. In addition, PA and PI of circulating Nph changed depending on the prevalence of RC, so a significant increase in these parameters was noted in the group of patients at stages III–IV RC relative to the group with stages I–II RC. According to previous studies [17], at the initial stages of lung cancer, NETs had cytotoxic properties in relation to cancer cells, and at later stages they demonstrated a pro-tumor effect. There is evidence that in breast cancer, Nph more actively form NETs in the presence of a tumor with G3 differentiation than G1 [18]. The formation of NETs is one of the mechanisms of “evasion” or shielding of cancer cells from the antitumor mechanisms of the immune system [19].

Our data indicate an increase in the ability of circulating Nph to form NETs, as well as an increase in their killing activity in groups with RP relative to patients with RBN and the control group. The correlation we found between the percentage of NETs (r = 0.438, p = 0.001), PA (r = 0.431, p = 0.001) and IP (r = 0.507, p = 0.001) of Nph with the stage of RC may indicate an increase in their cytotoxic properties depending on the prevalence of RC. We assessed the expression of surface receptors that determine activation, degranulation, phagocytic activity and maturity of Nph. A significant increase in the number of Nph expressing CD66b receptors was found both at the initial and widespread stages of RC (Table 3). An increase in the number of CD66b+ Nph may indicate an increase in activated, mature, degranulating circulating Nph in patients in the study groups. There is evidence of an increase in the number and ability to form IL‑1 in CD66b+ Nph in other types of cancer [20], which is consistent with the results of our study in RC.

Table 3
Changes in the expression of surface receptors of circulating neutrophils in the study groups, Ме (Q₁-Q₃)

Indicators		Control group (n = 22)	Renal benign neoplasms (n = 18)	Renal cancer stage I–II (n = 50)	Renal cancer stage III–IV(n = 34)
CD11b⁺	%	89.10 (82.00–90.90)	93.30 (85.00–93.90)	87.40 (72.64–95.20)	94.40 (73.30–97.90)
CD11b⁺	10⁹/л	2.94 (2.70–3.00)	2.4 (2.19–2.50)	3.02 (2.51–3.30)	3.27 (2.53–3.38)
CD16⁺	%	86.10 (82.00–89.70)	83.40 (82.00–89.50)	89.00 (72.20–95.00)	88.30 (61.20–94.40)
CD16⁺	10⁹/л	2.84 (2.71–2.96)	2.15 (2.11–2.42)	3.08 (2.49–3.31)	3.06 (2.12–2.27)
CD66b⁺	%	66.50 (57.80–77.20)	65.60 (60.10–67.60)	75.70 (62.80–86.90)	70.30 (59.50–79.30)
CD66b⁺	10⁹/л	2.26 (2.18–2.76)	2.24 (2.14–2.51)	2.62 (2.17–3.01)^*	2.43 (2.06–2.74)^*
p		-	-	p2 = 0.001	p1 = 0.012, p2 = 0.001
CD63⁺	%	82.80 (78.10–95.60)	78.30 (67.00–98.00)	86.10 (68.30–96.00)	81.30 (35.10–92.00)
CD63⁺	10⁹/л	2.73 (2.58–3.15)	2.02 (1.72–2.53)	2.98 (2.36–3.32)	2.81 (1.21–3.18)
CD11b⁺CD16⁺	%	86.30 (77.70–89.40)	81.70 (80.30–89.50)	82.00 (64.40–90.60)	86.50 (61.10–93.50)
CD11b⁺CD16⁺	10⁹/л	2.84 (2.56–2.95)	2.10 (2.07–2.31)	2.84 (2.23–3.13)	2.99 (2.11–3.24)

Note: p1 — reliability of differences in indicators from the values of the control group; p2 — reliability of differences in indicators from the values in the group with benign neoplasms; reliability of differences according to the Mann-Whitney criterion: * (p < 0.05).

Changes in the expression values of CD11b, CD16, CD63 receptors of circulating Nph in the study groups were statistically insignificant. In multivariate Cox regression, an increase in the risk of developing RC was revealed with an increase in the expression of CD66b, TI, PA and the PI of circulating Nph (OR² = 0.728, χ² = 58.1, p = 0.001). In the univariate logistic regression analysis for the differential diagnosis between renal RBN and RC, the following factors showed statistical significance: the percentage of CD66b+ Nph (OR 0.344 95% CI 0.128–0.559, p = 0.002), the TI (OR 9.173 95% CI 1.474–16.872, p = 0.020), PA of Nph (OR 1.555 95% CI 0.437–2.672, p = 0.006) and PIof Nph(OR 42.940 95% CI 12.259–73.622, p = 0.006). The area under the curve (AUC) of the model was 0.983, and RC could be diagnosed with a probability of 94.3% (Spec. = 0.889, Sens. = 0.962) (Figure).

Fig. ROC curve for the regression model of differential diagnosis of renal cancer and renal benign neoplasms taking into account the expression indicators of the CD66b receptor, the neutrophil extracellular traps index, phagocytic activity and the phagocytic activity index

We found a direct correlation between the change in the expression of the CD66b receptor and CD16 (r = 0.501, p = 0.001), as well as the CD66b receptor and CD63 (r = 0.688, p = 0.001) in groups of patients with stages I–II and stages III–IV RС. This may indicate an increase in the killing activity of neutrophils in the studied groups, since these receptors are markers of maturity, PA, the ability to degranulate and form NETs [21].

Conclusion

Thus, an increase in CD66b+ Nph and activation of extracellular traps release indicate an increase in the killing activity of Nph in RC. Simultaneous determination of the amount of CD66b+ Nph, TI, PA and the PI can be used for differential diagnosis between RBN and RC.